Vesatolimod

Drug Profile

Vesatolimod

Alternative Names: GS-9620

Latest Information Update: 24 Mar 2017

Price : $50

At a glance

  • Originator Gilead Sciences
  • Class Antivirals; Pteridines; Pyrrolidines; Small molecules
  • Mechanism of Action Toll-like receptor 7 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I HIV infections
  • Discontinued Hepatitis C

Most Recent Events

  • 02 Mar 2017 Gilead Sciences plans a phase Ib trial for HIV infection in USA (NCT03060447)
  • 13 Feb 2017 Preclinical data in HIV-1 infections presented at the 24th Conference on Retroviruses and Opportunistic Infections (CROI-2017)
  • 11 Nov 2016 Safety and pharmacodynamic results from the phase II trial presented at the The Liver Meeting® 2016: 67th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD - 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top